Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease

Research output: Contribution to journalArticle

Standard

Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. / Minthon, Lennart; Nilsson, Karin; Edvinsson, Lars; Wendt, P E; Gustafson, Lars.

In: Dementia and Geriatric Cognitive Disorders, Vol. 6, No. 5, 1995, p. 245-251.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease

AU - Minthon, Lennart

AU - Nilsson, Karin

AU - Edvinsson, Lars

AU - Wendt, P E

AU - Gustafson, Lars

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Faculty of Medicine (000022000), Medicine (Lund) (013230025), Clinical Memory Research Unit (013242610), Department of Psychogeriatrics (013304000)

PY - 1995

Y1 - 1995

N2 - Regional cerebral blood flow (rCBF) was studied in patients with Alzheimer's disease (AD) before and after 14 months of tacrine treatment. The treated group was compared with an identical reference group of untreated AD patients. At baseline the two groups showed an identical rCBF and mean hemispheric blood flow. After 14 months the tacrine-treated patients showed a stable rCBF level and a significant increase in rCBF in the central-parietal regions, compared to the untreated reference group, who showed typical AD reductions in rCBF in these regions. Clinical outcome: 7 of 9 patients in the tacrine group were clinically unchanged or slightly improved during the study time. In the untreated group 8 of 11 patients had deteriorated in clinical assessments and none had improved. Long-term tacrine treatment in Alzheimer's disease may delay the progression of symptoms.

AB - Regional cerebral blood flow (rCBF) was studied in patients with Alzheimer's disease (AD) before and after 14 months of tacrine treatment. The treated group was compared with an identical reference group of untreated AD patients. At baseline the two groups showed an identical rCBF and mean hemispheric blood flow. After 14 months the tacrine-treated patients showed a stable rCBF level and a significant increase in rCBF in the central-parietal regions, compared to the untreated reference group, who showed typical AD reductions in rCBF in these regions. Clinical outcome: 7 of 9 patients in the tacrine group were clinically unchanged or slightly improved during the study time. In the untreated group 8 of 11 patients had deteriorated in clinical assessments and none had improved. Long-term tacrine treatment in Alzheimer's disease may delay the progression of symptoms.

M3 - Article

VL - 6

SP - 245

EP - 251

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 5

ER -